Abstract
Background: The inherent plasticity of tumor cells provides a mechanism of resistance to molecularly targeted therapies, exemplified by adeno-to-neuroendocrine lineage transitions in prostate and lung cancer. Here we investigate the root cause of lineage plasticity following Trp53 and Rb1 loss in genetically engineered mouse models, murine and patient-derived organoid cultures, and patient biospecimens with castrate-resistant prostate cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
